Results 51 to 60 of about 68,781 (284)

Genetic diagnosis as a tool for personalized treatment of Duchenne muscular dystrophy [PDF]

open access: yes, 2016
Accurate definition of genetic mutations causing Duchenne muscular dystrophy (DMD) has always been relevant in order to provide genetic counseling to patients and families, and helps to establish the prognosis in the case where the distinction between ...
Bello, Luca, Pegoraro, Elena
core  

Rehabilitation interventions for foot drop in neuromuscular disease [PDF]

open access: yes, 2009
"Foot drop" or "Floppy foot drop" is the term commonly used to describe weakness or contracture of the muscles around the ankle joint.
Brumett   +33 more
core   +1 more source

Exploring AAV‐Mediated Gene Therapy for Inner Ear Diseases: from Preclinical Success to Clinical Potential

open access: yesAdvanced Science, EarlyView.
Current preclinical studies of AAV‐mediated gene therapy explore different strategies based on the characteristics of inner ear diseases. For genetic hearing loss, approaches include the replacement of a “good gene,” removal of a “bad gene,” or direct correction of mutations through base editing.
Fan Wu   +7 more
wiley   +1 more source

Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment [PDF]

open access: yes, 2018
Duchenne muscular dystrophy (DMD) is caused by loss of dystrophin protein, leading to progressive muscle weakness and premature death due to respiratory and/or cardiac complications.
Ball, V   +15 more
core   +2 more sources

Choroid Plexus Fibroblast–ILC2 Niche Promotes Adult Hippocampal Neurogenesis after Traumatic Brain Injury

open access: yesAdvanced Science, EarlyView.
This study investigates the role of group 2 innate lymphoid cells (ILC2) in the choroid plexus (ChP) following traumatic brain injury (TBI). ILC2 accumulation alleviates immune infiltration, preserves hippocampal integrity, and improves sensory‐motor and memory functions.
Shiqi Gao   +10 more
wiley   +1 more source

Are mice good models for human neuromuscular disease? Comparing muscle excursions in walking between mice and humans [PDF]

open access: yes, 2017
The mouse is one of the most widely used animal models to study neuromuscular diseases and test new therapeutic strategies. However, findings from successful pre-clinical studies using mouse models frequently fail to translate to humans due to various ...
A De Luca   +81 more
core   +2 more sources

Recent Advances in mRNA Delivery Systems for Cancer Therapy

open access: yesAdvanced Science, EarlyView.
This review systematically investigates the applications of mRNA therapy in cancer treatment, with particular emphasis on nonviral delivery systems, targeting strategies, stimulus‐responsive systems, and local delivery methods. Concluding with a meticulous evaluation, the review sheds light on the prevailing challenges while illuminating promising ...
Zheng Zhang   +9 more
wiley   +1 more source

The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development [PDF]

open access: yes, 2015
Despite multiple publications on potential therapies for neuromuscular diseases (NMD) in cell and animal models only a handful reach clinical trials. The ability to prioritise drug development according to objective criteria is particularly critical in ...
Allen, Hugh   +49 more
core   +4 more sources

Wearable Bioelectronics for Home‐Based Monitoring and Treatment of Muscle Atrophy

open access: yesAdvanced Science, EarlyView.
As an inevitable disease, muscle atrophy has received more attention. Because the factors that induce this disease are diverse, achieving a complete cure is still impossible. Wearable bioelectronics provides a more comfortable, low‐cost, and efficient way of home care for the monitoring and treatment of muscle atrophy. Therefore, this review summarizes
Shuai Zhang   +4 more
wiley   +1 more source

Translational and Regulatory Challenges for Exon Skipping Therapies [PDF]

open access: yes, 2014
Several translational challenges are currently impeding the therapeutic development of antisense-mediated exon skipping approaches for rare diseases. Some of these are inherent to developing therapies for rare diseases, such as small patient numbers and ...
Aartsma-Rus, A   +14 more
core   +2 more sources

Home - About - Disclaimer - Privacy